Philip Bruggmann

6.0k total citations
73 papers, 1.2k citations indexed

About

Philip Bruggmann is a scholar working on Hepatology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Philip Bruggmann has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hepatology, 49 papers in Epidemiology and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Philip Bruggmann's work include Hepatitis C virus research (57 papers), Liver Disease Diagnosis and Treatment (32 papers) and Hepatitis B Virus Studies (31 papers). Philip Bruggmann is often cited by papers focused on Hepatitis C virus research (57 papers), Liver Disease Diagnosis and Treatment (32 papers) and Hepatitis B Virus Studies (31 papers). Philip Bruggmann collaborates with scholars based in Switzerland, United States and Australia. Philip Bruggmann's co-authors include Alain H. Litwin, Jason Grebely, Luis Falcato, Francesco Negro, Olav Dalgård, Gregory J. Dore, Markus Backmund, Geert Robaeys, Beat Müllhaupt and Tracy Swan and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Hepatology.

In The Last Decade

Philip Bruggmann

67 papers receiving 1.2k citations

Peers

Philip Bruggmann
Maryam Alavi Australia
Benjamin Eckhardt United States
Heather Valerio Australia
Deepak Suri United Kingdom
Carolyn Wester United States
Sarah Kattakuzhy United States
Tamara McDonald United Kingdom
Maryam Alavi Australia
Philip Bruggmann
Citations per year, relative to Philip Bruggmann Philip Bruggmann (= 1×) peers Maryam Alavi

Countries citing papers authored by Philip Bruggmann

Since Specialization
Citations

This map shows the geographic impact of Philip Bruggmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Bruggmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Bruggmann more than expected).

Fields of papers citing papers by Philip Bruggmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Bruggmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Bruggmann. The network helps show where Philip Bruggmann may publish in the future.

Co-authorship network of co-authors of Philip Bruggmann

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Bruggmann. A scholar is included among the top collaborators of Philip Bruggmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Bruggmann. Philip Bruggmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baggio, Stéphanie, Philip Bruggmann, Anna Schoeni, et al.. (2025). Efficacy of e-cigarettes for smoking cessation in populations with psychiatric and/or substance use problems: A secondary analysis of a randomized controlled trial. Tobacco Prevention & Cessation. 11(February). 1–10. 2 indexed citations
4.
Bruggmann, Philip, Oliver Senn, Anja Frei, et al.. (2022). High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study. Swiss Medical Weekly. 152(102). w30122–w30122. 5 indexed citations
5.
6.
Bruggmann, Philip, et al.. (2021). Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. Journal of Preventive Medicine and Public Health. 54(4). 251–258. 24 indexed citations
7.
Bruggmann, Philip, et al.. (2020). Hepatitis-C-Behandlungen in der hausärztlichen Praxis. 1 indexed citations
8.
Bruggmann, Philip, et al.. (2019). The Swiss Hepatitis Strategy as a model for facing future health policy challenges. Health Policy. 123(7). 681–687. 3 indexed citations
9.
Grischott, Thomas, Luis Falcato, Oliver Senn, Milo A. Puhan, & Philip Bruggmann. (2019). Chronic obstructive pulmonary disease (COPD) among opioid‐dependent patients in agonist treatment. A diagnostic study. Addiction. 114(5). 868–876. 13 indexed citations
10.
Hellard, Margaret, Carla Treloar, Julie Bruneau, et al.. (2018). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International. 39(1). 20–30. 83 indexed citations
11.
Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2018). Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE. 13(12). e0209374–e0209374. 9 indexed citations
12.
Lamoury, F., Behzad Hajarizadeh, Evan B. Cunningham, et al.. (2017). Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology. 92. 32–38. 24 indexed citations
13.
Grebely, Jason, Geert Robaeys, Philip Bruggmann, et al.. (2015). Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy. 26(10). 1028–1038. 135 indexed citations
14.
Falcato, Luis, et al.. (2015). Qualität der Hepatitis-C-Abklärung bei Patienten in Opioid-Substitutionstherapie im Kanton Zürich. Zurich Open Repository and Archive (University of Zurich). 17(6). 259–264. 1 indexed citations
15.
Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2015). Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE. 10(6). e0125214–e0125214. 22 indexed citations
16.
Bruggmann, Philip & Jason Grebely. (2014). Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy. 26. S22–S26. 73 indexed citations
17.
Bruggmann, Philip, et al.. (2014). Birth year distribution in reported hepatitis C cases in Switzerland. European Journal of Public Health. 25(1). 141–143. 8 indexed citations
18.
Robaeys, Geert, Jason Grebely, Stefan Mauss, et al.. (2013). Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases. 57(suppl 2). S129–S137. 86 indexed citations
19.
Fretz, R., Francesco Negro, Philip Bruggmann, et al.. (2013). Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Medical Weekly. 143(1920). w13793–w13793. 26 indexed citations
20.
Broers, Barbara, et al.. (2008). Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit - Erstellt durch die Schweizerische Gesellschaft für Suchtmedizin. Bern Open Repository and Information System (University of Bern). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026